vs
Side-by-side financial comparison of Magyar Bancorp, Inc. (MGYR) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
TriSalus Life Sciences, Inc. is the larger business by last-quarter revenue ($13.2M vs $8.9M, roughly 1.5× Magyar Bancorp, Inc.). Magyar Bancorp, Inc. runs the higher net margin — 35.4% vs -73.9%, a 109.3% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 19.0%). Magyar Bancorp, Inc. produced more free cash flow last quarter ($3.7M vs $-2.5M).
Magyar Bank is a bank based in New Brunswick, New Jersey with branches in Central Jersey.
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
MGYR vs TLSI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.9M | $13.2M |
| Net Profit | $3.1M | $-9.8M |
| Gross Margin | — | 86.7% |
| Operating Margin | 48.3% | -24.8% |
| Net Margin | 35.4% | -73.9% |
| Revenue YoY | 19.0% | 59.8% |
| Net Profit YoY | 50.4% | 3.5% |
| EPS (diluted) | $0.50 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.9M | $13.2M | ||
| Q3 25 | — | $11.6M | ||
| Q2 25 | — | $11.2M | ||
| Q1 25 | — | $9.2M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | — | $7.3M | ||
| Q2 24 | $7.2M | $7.4M | ||
| Q1 24 | $7.5M | $6.5M |
| Q4 25 | $3.1M | $-9.8M | ||
| Q3 25 | — | $-10.8M | ||
| Q2 25 | — | $-8.3M | ||
| Q1 25 | — | $-10.4M | ||
| Q4 24 | — | $-10.1M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $1.7M | $-4.3M | ||
| Q1 24 | $1.9M | $-13.2M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
| Q4 25 | 48.3% | -24.8% | ||
| Q3 25 | — | -77.9% | ||
| Q2 25 | — | -65.4% | ||
| Q1 25 | — | -79.9% | ||
| Q4 24 | — | -91.8% | ||
| Q3 24 | — | -118.9% | ||
| Q2 24 | 30.5% | -111.0% | ||
| Q1 24 | 32.1% | -180.8% |
| Q4 25 | 35.4% | -73.9% | ||
| Q3 25 | — | -93.5% | ||
| Q2 25 | — | -73.9% | ||
| Q1 25 | — | -113.2% | ||
| Q4 24 | — | -122.4% | ||
| Q3 24 | — | -32.6% | ||
| Q2 24 | 23.5% | -58.8% | ||
| Q1 24 | 25.1% | -204.5% |
| Q4 25 | $0.50 | $-0.22 | ||
| Q3 25 | — | $-0.96 | ||
| Q2 25 | — | $-0.27 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | $0.27 | $-0.21 | ||
| Q1 24 | $0.30 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.1M | $20.4M |
| Total DebtLower is stronger | $49.1M | — |
| Stockholders' EquityBook value | $121.7M | $-33.9M |
| Total Assets | $1.0B | $35.3M |
| Debt / EquityLower = less leverage | 0.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.1M | $20.4M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | $49.0M | $16.5M | ||
| Q1 24 | $50.0M | $4.0M |
| Q4 25 | $49.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $121.7M | $-33.9M | ||
| Q3 25 | — | $-26.7M | ||
| Q2 25 | — | $-19.4M | ||
| Q1 25 | — | $-34.4M | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | $-20.4M | ||
| Q2 24 | $109.0M | $-25.3M | ||
| Q1 24 | $107.6M | $-36.0M |
| Q4 25 | $1.0B | $35.3M | ||
| Q3 25 | — | $36.5M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $28.6M | ||
| Q4 24 | — | $24.0M | ||
| Q3 24 | — | $27.5M | ||
| Q2 24 | $944.4M | $32.4M | ||
| Q1 24 | $928.6M | $17.9M |
| Q4 25 | 0.40× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $-2.5M |
| Free Cash FlowOCF − Capex | $3.7M | $-2.5M |
| FCF MarginFCF / Revenue | 41.4% | -19.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | $8.7M | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $-2.5M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-7.3M | ||
| Q1 25 | — | $-4.5M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | $1.7M | $-13.4M | ||
| Q1 24 | $553.0K | $-10.9M |
| Q4 25 | $3.7M | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | — | $-5.8M | ||
| Q3 24 | — | $-11.0M | ||
| Q2 24 | $1.5M | $-13.5M | ||
| Q1 24 | $428.0K | $-10.9M |
| Q4 25 | 41.4% | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | — | -69.7% | ||
| Q3 24 | — | -149.9% | ||
| Q2 24 | 21.5% | -183.1% | ||
| Q1 24 | 5.7% | -169.3% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | 2.0% | 0.8% | ||
| Q1 24 | 1.7% | 1.0% |
| Q4 25 | 1.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
